Canadian cannabis cultivation, research, processing, and distribution company, Tilray (NASDAQ: TLRY) has announced its support of two clinical cannabis studies taking place domestically and overseas.
“We are committed to advancing cannabinoid-based science to further understand the potential benefits of medical cannabis as a treatment option among these critical patient populations,” said Tilray Global Patient Research and Access Vice President, Philippe Lucas. “There is a serious need for more clinical data in our field, and we are proud to support research like this around the world.”
Tilray has become the cannabidiol (CBD) supplier for an Australian pilot study at the Murdoch Children’s Research Institute (MCRI) in Melbourne focused on reducing Severe Behavioral Problems (SBP) in children with intellectual disabilities.
The trial commenced in early 2019 shortly after receiving cannabis products from Tilray’s facility in Nanaimo, British Columbia.
According to Tilray, current research indicates that patients with SBP experience fewer side effects with CBD and other cannabis extracts than they do from the use of other conventional anti-psychotic and psychotropic medications which can result in weight gain, metabolic syndrome, and extrapyramidal movement disorders.
The study involves ten participants between the ages of 8 and 16 who receive either a placebo or the Tilray C100 oral CBD solution. The results of the study are expected to be available by 2020.
Tilray will also be supplying low-dose capsules with a balance of tetrahydrocannabinol (THC) and CBD for a Canadian study focused on improving the quality of life for people living with HIV. The trial will also include doses of a low-THC/mid-to-high-CBD concentration capsule and take place at the McGill University Division of Infectious Diseases and Chronic Viral Illness in Montreal, Quebec.
The 12-week trial, which is expected to begin in the second half of 2019, will measure the safety, tolerability, and effectiveness of the Tilray capsules on immune activation in 26 participants over the age of 18 who have been diagnosed with HIV.
More information about the trial is expected to be released in the coming months.